Cancer Res (2025) 85 (8_Supplement_2): CT017. Clinical benefit of first generation BRAF inhibitors (BRAFi) as monotherapy is limited due to paradoxical feedback activation of downstream MAPK or EGFR; ...
Cancer Immunol Res (2026) 14 (2_Supplement): C008.
Cancer Res (2026) 86 (8_Supplement): LB407.
Introduction: Epigallocatechin gallate (EGCG) is a polyphenol present in green tea that is known for its anti-oxidant, anti-inflammatory, anti-angiogenic, pro-apoptotic, and anti-cancer properties.
Introduction and Background: Salmonella-IL2 (Saltikva) is an attenuated strain of orally administered Salmonella that carries the human gene for IL-2 that colonizes the tumor microenvironment and ...
Abstract. Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 monoclonal antibody linked to a potent DNA topoisomerase I (TOP1) inhibitor payload ...
Cancer Res (2024) 84 (7_Supplement): LB123.
Abstract. Conventional therapies targeted towards the primary tumor cell oftentimes do not affect the metastatic cell and, in fact, may promote metastasis. For these reasons, our research has focused ...
You do not currently have access to this content.
Abstract:. AJ1-11095, a type II JAK2 inhibitor being developed for myelofibrosis, led to impressive clinical responses in a recent phase I study, suggesting that the drug, and perhaps the rest of its ...
Cancer Res (2025) 85 (8_Supplement_2): LB427. Approximately 15% of all cancers harbor homozygous MTAP deletions, which are associated with poor prognoses. MTAP loss leads to the accumulation of ...
Cyclin-dependent kinases (CDKs) are an attractive class of cancer targets due to their role in cell-cycle regulation. CDK2 is a Ser/Thr kinase activated via interaction with its cyclin partners CCNE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results